LAG3 and metastatic melanoma: Indeed, relatlimab, a first-in-class LAG3 inhibitor, was recently approved for the first-line treatment of metastatic melanoma in combination with the anti-PD-1 antibody nivolumab, improving progression-free survival and response rates compared to anti-PD-1 alone.